White blood cell treatment aids wound healing

07/10/2013 | Wall Street Daily

A concentrated mixture of white blood cells has demonstrated an ability to heal persistent wounds of patients suffering from diabetes or restricted blood flow. The treatment, called CureXcell, has a 70% success rate in closing the wounds of 5,000 patients to date, according to its developer, the Israeli company MacroCure. CureXcell is undergoing a Phase III trial in the United States, and the company hopes to have FDA approval by 2017.

View Full Article in:

Wall Street Daily

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA